Dr. Dayan Goodenowe, biomedical researcher and founder of Prodrome Sciences, announced the marketing clearance and commercial launch of the company’s flagship plasmalogen supplements, ProdromeNeuro™ and ProdromeGlia™, in Japan, the company said. These dietary supplements are designed to support healthy plasmalogen levels, essential lipids involved in cell membrane structure and oxidative stress modulation, which decline with age and in certain disease states.
The Japan launch is being led by Dr. Yasuyo Yamazaki, president of Prodrome Japan Inc., which will oversee distribution and scientific collaborations for Prodrome Sciences products in the Japanese market. The supplements are now available through the official online store and on Amazon Japan, making them accessible to consumers and supporting ongoing research efforts in collaboration with Japanese medical and scientific organisations.
ProdromeNeuro™ contains omega-3 plasmalogen precursors formulated to support synaptic communication, cognitive clarity and overall brain health, while ProdromeGlia™ uses omega-9 plasmalogen precursors intended to support brain, myelin and white matter integrity alongside balanced inflammatory responses. Both products are manufactured in the United States under current Good Manufacturing Practices (cGMP).
According to the announcement, the commercial launch in Japan reflects decades of collaborative research with Japanese scientists, many of whom have conducted foundational studies on plasmalogens, and represents a milestone in making these supplements widely available for consumer use in a market long engaged in advanced plasmalogen research.
Prodrome Japan Inc. will continue scientific engagement and distribution efforts to support broader availability and integration of plasmalogen supplements across consumer and institutional channels in Japan.
